BMS Striving to Push Opdivo Past Keytruda
Sunday, September 28, 2014
Source: Medical Marketing & Media
Timing may not be everything. While Merck's Keytruda was the first PD-1 inhibitor to debut in the US, one analyst says that Bristol-Myers Squibb could wind up the long-term winner in this category.
The FDA approved Keytruda (pembrolizumab) on September 4th for second-line use in patients with unresectable or metastatic melanoma, but before Keytruda could land on US shores a week later, BMS and its partner company Ono Pharmaceuticals had already begun launching Opidivo in Japan, making it the first of the new—and highly touted—class of cancer drugs to be made available.